ArticleEcancermedicalscience2025
PD-1 or PD-L1 inhibitors in addition to first-line chemotherapy for endometrial cancer: an extracted individual patient data meta-analysis.
Article in Ecancermedicalscience, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed, 3 syntheses or guidelines pooled it.
- Predictive value of PD-L1 expression and dMMR/pMMR status for immune checkpoint inhibitor combined with chemotherapy in advanced/recurrent endometrial cancer: a meta-analysis.World journal of surgical oncology · 2026Pooled it
- PD-1/PD-L1 inhibitors plus chemotherapy as first-line therapy for advanced or metastatic endometrial cancer: a systematic review and meta-analysis of randomized controlled trials.Frontiers in immunology · 2026Pooled it
- Efficacy of PD-1/PDL-1 inhibitors for ovarian cancer: a systematic review and network meta-analysis.Future oncology (London, England) · 2025Pooled it
- The economic value of mismatch repair-guided immunotherapy in endometrial cancer: companion testing and patient selection.Frontiers in medicine · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: To assess the impact of PD-1/PD-L1 inhibitors in first-line treatment of advanced or recurrent endometrial cancer (EC) through individual patient data (IPD) Meta-analysis, providing insights by integrated survival curves. Methods: We searched PubMed, Embase, Cochrane and meetings up to April 2024 for randomised phase II or III trials (randomised controlled trials) investigating immunotherapy plus chemotherapy for EC. IPD was reconstructed from Kaplan-Meier plots using WebPlotDigitizer and the R package IPDfromKM, and then combined. Results: NRG-GY018, RUBY, MITO END-3, AtTEnd/ENGOT-en7 and DUO-E were included. 2,436 patients were analysed for progression-free survival (PFS) and 2,317 for overall survival (OS). Among these, 621 patients had deficient DNA mismatch repair (dMMR) and 1,815 had the proficient disease (pMMR).The IPD analysis highlighted the significant benefit of adding immunotherapy to chemotherapy in dMMR patients, with 3-year absolute gains of 36% in PFS (HR 0.36, 95% CI 0.28-0.45) and 28% in OS (HR 0.41, 95% CI 0.30-0.48).For pMMR, a smaller benefit was observed in PFS, with a 3-year absolute gain of 6% (HR 0.78, 95% CI 0.69-0.88). Notably, a significant benefit occurred only with PD-1 inhibitors (PFS HR 0.66, 95% CI 0.55-0.79; OS: HR 0.78, 95% CI 0.62-0.96). No significant benefit was seen with PD-L1 inhibitors (PFS: 0.87, 95% CI 0.75-1.03; OS: HR: 0.93, 95% CI 0.75-1.16). Conclusion: This meta-analysis validated the benefit of adding immunotherapy to platinum-based chemotherapy with respect to PFS. dMMR patients gain advantages from the inclusion of either anti-PD-1 or anti-PD-L1 agents, whereas pMMR patients only experience this benefit when treated with anti-PD-1 agents.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.